CompletedNCT02589262
AUT00206 Safety, Blood Levels and Effects in Schizophrenia
About this title
Read the official source — NCT02589262Medication studyAges 18–45United Kingdom
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateSeptember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Autifony Therapeutics Limited
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02589262
- Official title
Show the full official title
A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Autifony Therapeutics Limited.
Did this study involve medication?
Yes. The study involved medication, including AUT00206.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
